Vittoria Biotherapeutics Announces Keith Westby as Chief Operating Officer PHILADELPHIA, April 16, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage cell therapy company, has announced that Keith Westby has joined the company as its inaugural Chief...

Vittoria Biotherapeutics Announces Appointment of Life Sciences Veteran Rosemary Mazanet, M.D., Ph.D. as Chief Medical Officer PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage cell therapy company, has announced today that accomplished life sciences leader, Rosemary Mazanet, M.D.,...

Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma VIPER-101 is an autologous, CD5 knock-out CAR-T therapy for the treatment of T-cell lymphoma Initiating first-in-human Phase 1 trial in H1 of 2024 PHILADELPHIA, Dec. 07, 2023 (GLOBE NEWSWIRE) --...

Vittoria Biotherapeutics Announces the Presentation of New Data Supporting the Company's Platform at the 65th American Society of Hematology Annual Meeting PHILADELPHIA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics announced the presentations of abstracts authored by researchers at the University of Pennsylvania and a poster authored by...

Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies PHILADELPHIA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics today announced it has secured over $15 million in a private financing round. The funds will be used to continue advancing...